Is an abbreviated bronchial challenge with histamine valid?

Area of Science:

• Pulmonary Medicine
• Allergy and Immunology
• Clinical Pharmacology

Background:

• Nonspecific bronchial reactivity testing is crucial for diagnosing and managing asthma.
• Histamine is a key bronchoprovocative agent distinct from methacholine, offering potential clinical advantages.
• Standard histamine challenge protocols can be time-consuming, prompting the need for efficient alternatives.

Purpose of the Study:

• To validate abbreviated protocols for histamine-induced bronchial reactivity testing.
• To compare the accuracy and efficiency of abbreviated histamine challenge protocols against the standard method.
• To assess the clinical utility of shortened histamine testing in patients with asthma.

Main Methods:

• A validation study involving 24 asthma patients was conducted.
• Two abbreviated histamine challenge protocols were compared to the standard protocol.
• Protocols were randomized, with challenges separated by one week, measuring FEV1 at different intervals.

Main Results:

• Abbreviated protocols significantly reduced administration time (18-30 min vs. 44 min).
• No significant differences were found in the provocative dose (PD20 FEV1) or dose-response curve slope.
• High agreement was observed between abbreviated and standard protocols for PD20 FEV1 and curve slope.

Conclusions:

• Abbreviated histamine challenge protocols are effective and comparable to the standard protocol for assessing bronchial reactivity.
• These shorter protocols offer a more time-efficient alternative for histamine-based airway challenge testing.
• The findings support the use of abbreviated histamine protocols in clinical and investigative settings for asthma evaluation.